Dual CAR T-cell targeting CD19/Ig-kappa for safer Lymphoma therapy

BUSINESS OPPORTUNITY

This new CAR T-cell can be developed to treat children and adults with B cell lymphoma. Inven2 is seeking to out-license the technology to pharmaceutical companies and/or biotechnology SMEs for clinical trials either as a single intervention or combination treatment with existing first, second, or third line interventions. B cell Lymphoma is a cause of significant morbidity and mortality. The field of immunotherapy represents a market of 100 billion US dollars and is growing steadily.

TECHNOLOGY

CAR T cell therapy (autologous or allogeneic) that recognizes malignant B cells expressing IgKappa and CD19 but not IgLambda. This design enables a safer approach to treat B cell lymphoma as it will not deplete all B cells, including the healthy B cells, only the B cells that express IgKappa and CD19.

ADVANTAGES

Our data demonstrates an effective and highly significant reduction in tumour cells when tested for killing malignant B cell lymphoma cells in vitro.

PUBLICATIONS

Publication is available here (conference abstract) and here (full paper).

INTELLECTUAL PROPERTY

Priority patent application filed in Norway in 2018.

WO2020011706 entered national phase in USA and Europe.

Magdalena Gjefle, M.Sc.

Magdalena Gjefle, M.Sc.

Business Development and Licensing Executive

Innovation

+47 41 68 50 18

magdalena.gjefle@inven2.com